ArticleLancet regional health. Americas2026
Temporal trends in the epidemiology of primary biliary cholangitis in the public healthcare system of Brazil: a large population-based study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Population-based data on the epidemiology of primary biliary cholangitis (PBC) in Latin America are lacking. We aimed to characterise incidence, prevalence, and geographic patterns of PBC within Brazil's public healthcare system. Methods: We performed a nationwide population-based retrospective study using de-identified administrative data from the Unified Health System (DATASUS), curated through an artificial intelligence platform. Adults (≥16 years) with ICD-10 code K74.3 and public dispensation of ursodeoxycholic acid between 1 January 2021 and 31 December 2024 were included. Annual World Health Organization (WHO) age-standardised incidence and prevalence were estimated by sex, age group, and macroregion. Temporal trends were modelled with log-linear regression to obtain average annual percent change (AAPC). Correlation with macroregional Human Development Index (HDI) was explored. Findings: We identified 10,125 PBC patients [77.75% (7872) women; mean age 54.95 ± 20 years], within a nationwide dataset comprising approximately 230 million records. Age-standardised prevalence increased from 10.5 to 17.8 per 100,000 people (AAPC +18.2%; 95% CI: 12.5; 24.3%); while age-standardised incidence modestly declined from 4.00 to 3.42 per 100,000 person-years (AAPC -5.0%; 95% CI: -6.3; -3.7%). The female-to-male prevalence ratio in 2024 was 3.67:1, with peak rates at ages 66-70 years. A marked south-north gradient was observed, with highest rates in the South and Southeast and lowest in the North and Northeast; macroregional HDI showed a positive correlation with both incidence and prevalence. Interpretation: In Brazil, PBC is characterised by rising prevalence, relatively stable incidence, a narrower female predominance than historically reported, and marked geographic inequalities. These findings suggest possible under-recognition in less developed regions and provide a foundation for targeted public health strategies. The observed south-north gradient warrants further investigation in relation to environmental, socioeconomic, and healthcare-access factors. Funding: This study is supported by a research grant from IPSEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.